Founded on the proprietary, robust and well characterized Natural Killer (NK) cell expansion technology pioneered by Dario Campana, Nkarta aims to build the next generation of cell therapies. NK cells play a key role in the body’s immune system. They are able to identify and kill abnormal cells by monitoring their expression of activating and inhibitory receptors. Further, NK cells can recruit adaptive immune effectors to generate responses that are specific and durable.
Nkarta will combine its NK expansion platform with further proprietary cell engineering technologies to build differentiated products designed to tackle challenging diseases with significant unmet clinical need.